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Introduction {#sec001}
============

*Mycobacterium tuberculosis* (Mtb) is the causative bacterial agent of the global tuberculosis (TB) epidemic, which is now the biggest infectious disease killer worldwide, causing 1.6 million deaths in 2017 alone \[[@pcbi.1007533.ref001]\]. Mtb is an unusual bacterial pathogen, as it is able to cause both acute life threatening disease and a clinically latent infections that can persist for the lifetime of the human host \[[@pcbi.1007533.ref002],[@pcbi.1007533.ref003]\]. Metabolic reprogramming in response to the host niche during both the acute and the chronic phase of TB infections is a crucial determinant of virulence \[[@pcbi.1007533.ref004]--[@pcbi.1007533.ref007]\]. With the worldwide spread of multi- and extensively-resistant strains of Mtb thwarting the control of this global emergency, new drugs against Mtb are urgently needed and metabolic pathways present attractive and potentially powerful targets \[[@pcbi.1007533.ref008],[@pcbi.1007533.ref009]\].

Genome-scale constraint-based modelling has proved to be a powerful method to probe the metabolism of Mtb. The first Genome Scale Metabolic Networks (GSMNs) of Mtb were published in 2007 by Beste (GSMN-TB) \[[@pcbi.1007533.ref010]\] and Jamshidi (iNJ661) \[[@pcbi.1007533.ref010],[@pcbi.1007533.ref011]\] and have been used as a platform for interrogating high throughput 'omics' data, by simulating bacterial growth, generating hypothesis and informing drug discovery. Subsequently, these two original models were iteratively improved to expand both their scope and accuracy \[[@pcbi.1007533.ref012]--[@pcbi.1007533.ref020]\], to give us a current total of 16 inter-related GSMN of Mtb ([Fig 1](#pcbi.1007533.g001){ref-type="fig"}).

![The evolution of Genome Scale Metabolic models of Mtb.\
Models highlighted in grey were analysed in this study. Numbers denote genes/intracellular reactions. Black circles are indicative of merged Mtb models.](pcbi.1007533.g001){#pcbi.1007533.g001}

The first modifications to the two original models were carried out by Colijn *et al*. who built MFF-RmwBo \[[@pcbi.1007533.ref021]\], by adding the mycolic acid producing sub-model of Raman *et al*. (MAP, [Fig 1](#pcbi.1007533.g001){ref-type="fig"}) to GSMN-TB \[[@pcbi.1007533.ref022]\]. Fang *et al*. \[[@pcbi.1007533.ref023]\] systematically modified iNJ661 to produce iNJ661v, a model designed to describe Mtb growing *in vivo*. \[[@pcbi.1007533.ref024],[@pcbi.1007533.ref025]\]. Bordbar *et al*. expanded the utility of the Mtb GSMNs by building the first integrated human macrophage--Mtb genome-scale reconstruction, iAB-AMØ-1410-Mt-661 \[[@pcbi.1007533.ref026]\]. This host-pathogen model combined the original iNJ661 with a cell-specific alveolar macrophage model derived from the first human metabolic reconstruction Recon 1 \[[@pcbi.1007533.ref027]\]. A 2017 update of this model was subsequently used to evaluate 'omics' data and predict substrate availability within TB infected macrophages \[[@pcbi.1007533.ref028]\]. These advances were followed by a further complex series of updates and mergers to provide the wide selection of models we have today. Chindelevitch *et al*. used the algorithm, MetaMerge \[[@pcbi.1007533.ref012]\], to combine GSMN-TB and iNJ661 to improve the predictive value for high throughput genome essentiality data, while Lofthouse *et al*. \[[@pcbi.1007533.ref014]\] published GSMN-TB 1.1, an improved and extended version of GSMN-TB that successfully predicted sole nitrogen and carbon substrate utilization patterns. In 2014, Vashisht *et al*. published a curated and updated genome-scale model (iOSDD890) based on iNJ661, informed by a comprehensive manual re-annotation of the Mtb genome \[[@pcbi.1007533.ref016]\]. However, this model lacked β-oxidation pathways, rendering it unable to grow on fatty acids \[[@pcbi.1007533.ref020]\]. Also in 2014, Rienksma *et al*. combined three of the previously published models \[[@pcbi.1007533.ref015]\] to construct a new model, sMtb, followed, in 2018, with an improved version (sMtb 2018) designed for modelling Mtb metabolism inside macrophages \[[@pcbi.1007533.ref029],[@pcbi.1007533.ref030]\]. Finally, the first consolidated GSMN, iEK1011 was constructed using standardized nomenclature of metabolites and reactions from the BiGG database \[[@pcbi.1007533.ref031],[@pcbi.1007533.ref032]\]. These updates and revisions, combined with the availability of omics data have provided the TB community with models that have better accuracy and scope when compared to earlier GSMN-TB iterations \[[@pcbi.1007533.ref033]\].

With so many well-annotated GSMN's of Mtb available ([Fig 1](#pcbi.1007533.g001){ref-type="fig"}), a crucial first step in any genome scale exploration of the metabolism of Mtb is the selection of an appropriate model. Here, we systematically evaluate the performance of eight recently published Mtb-H37Rv GSMNs. In addition to comparing the metrics of the models descriptively in terms of size, connectivity, number of blocked reactions and gaps in the network, we also identify the thermodynamically infeasible, and energy generating cycles that could significantly impact on the accuracy of flux simulations. Using Flux Balance Analysis (FBA) and Flux Variability Analysis (FVA) we perform growth analysis and compare the models' ability to predict gene essentiality when grown on different carbon and nitrogen sources including cholesterol, a physiologically relevant carbon source for Mtb growing within its human host.

This work provides an inventory of the available GSMN-TB and their utility in recapitulating aspects of Mtb metabolism. In addition, we present updated versions of the best performing models iEK1011 and sMtb2018 (iEK1011_2.0 and sMtb2.0) for the TB research community to use in order to study the metabolism of this deadly pathogen.

Results and discussion {#sec002}
======================

Descriptive evaluation of the models {#sec003}
------------------------------------

Each of the GSMNs analysed in this study ([Fig 1](#pcbi.1007533.g001){ref-type="fig"}, [S1 Appendix](#pcbi.1007533.s001){ref-type="supplementary-material"}) combine knowledge from genome annotations, literature and measured biochemical compositions of Mtb. The complex linkage between genotype and phenotype is made by gene-protein-reaction (GPR) associations, implemented as Boolean rules in order to connect gene functions to enzyme complexes, isozymes or promiscuous enzymes, and finally to biochemical reactions \[[@pcbi.1007533.ref034]\]. Using set theory, we computed the intersection between all sets of the models' genes ([Fig 2](#pcbi.1007533.g002){ref-type="fig"}, and [S1 Table](#pcbi.1007533.s006){ref-type="supplementary-material"}). In accordance with expectations, the pairwise matrix ([Fig 2](#pcbi.1007533.g002){ref-type="fig"}) demonstrates that Mtb models constructed from the same ancestor (iNJ661 or GSMN-TB), are more similar ([Fig 1](#pcbi.1007533.g001){ref-type="fig"}, [Fig 2](#pcbi.1007533.g002){ref-type="fig"}). By contrast the consolidated models iEK1011 and sMtb2018 share gene similarities (\>60%, \<85% for iEK1011; and \>60%, \<98.4%) with all the other models demonstrating an independence from iNJ661 and GSMN-TB.

![Pairwise matrix of shared genes among Mtb models.\
Values in black (genes in common between the models), green and red text represent the number and percentage of Mtb model genes specified in the y- and x-axis, respectively.](pcbi.1007533.g002){#pcbi.1007533.g002}

All the models contain essential metabolic pathways such as carbon, nitrogen, nucleotides, and cofactor metabolism ([S2 Table](#pcbi.1007533.s007){ref-type="supplementary-material"}), encoded by 479 common genes that can be used to construct a core metabolic network for Mtb \[[@pcbi.1007533.ref035]\]. The models sMtb, sMtb2018 and iEK1011 had the greatest coverage of GPR associations and contain genes associated with survival and virulence within the host such as transport, respiratory chain, fatty acid metabolism, dimycocerosate esters and mycobactin metabolism ([S3 Table](#pcbi.1007533.s008){ref-type="supplementary-material"}) and are therefore good candidates to study Mtb metabolism during intracellular growth \[[@pcbi.1007533.ref036],[@pcbi.1007533.ref037]\].

In contrast, iOSDD890 ([Fig 1](#pcbi.1007533.g001){ref-type="fig"}) contains a high percentage of genes associated with nitrogen, propionate, pyrimidine, peptidoglycan, pyruvate and cofactor metabolism, but has a lower percentage of genes associated with glycerophospholipid metabolism, cholesterol degradation and fatty acid biosynthesis. Likewise, the iNJ661v_modified model ([Fig 1](#pcbi.1007533.g001){ref-type="fig"}) has a small number of genes involved in lipid-metabolism (e.g. β-oxidation, cholesterol degradation, fatty acid biosynthesis, lipid biosynthesis and mycolic acid biosynthesis). These models therefore have limitations for *in silico* simulation of Mtb growing on these physiologically relevant lipid sources and therefore also modelling *in vivo* growth.

Checking mass and charge balances of biochemical reactions {#sec004}
----------------------------------------------------------

Currency metabolites like water, protons, ATP, and cofactors like NADH, NADPH, FADH~2~, CoA, etc. are ubiquitous and essential for metabolism. The addition of these cofactor metabolites in GSMNs, and in particular their inclusion in the biomass reaction, considerably improves phenotype predictions and is a hallmark of good quality reconstructions \[[@pcbi.1007533.ref019],[@pcbi.1007533.ref038]\]. In order to check currency metabolites we converted the GSMNs into substance graphs (using a local script) where metabolites (nodes) are connected by edges (undirected and unweighted) if they appear in the same reaction \[[@pcbi.1007533.ref039]\] and computed node degrees (number of edges connected to the node) ([Table 1](#pcbi.1007533.t001){ref-type="table"} and [S4 Table](#pcbi.1007533.s009){ref-type="supplementary-material"}).

10.1371/journal.pcbi.1007533.t001

###### Degree values for currency metabolites of Mtb GSMNs.

PI: Phosphate, PPI: diphosphate, ACP: acyl-carrier protein, MK: menaquinone.
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  Currency Metabolite   GSMN-TB1.1   iOSDD890   sMtb   iCG760   iSM810   iNJ661v_mod   iEK1011   sMtb2018
  --------------------- ------------ ---------- ------ -------- -------- ------------- --------- ----------
  **H**                 72           701        512    102      127      667           741       511
  **CO**~**2**~         150          202        266    146      160      193           204       268
  **H**~**2**~**O**     5            507        624    0        5        472           569       624
  **ATP**               236          353        320    264      242      295           315       320
  **AMP**               101          170        115    103      103      117           132       115
  **PI**                189          293        266    213      196      268           293       267
  **PPI**               175          235        180    177      180      168           196       181
  **COA**               175          163        230    175      190      142           194       230
  **ACP**               98           48         136    94       103      48            57        136
  **NADH**              102          141        262    104      113      111           176       263
  **NADPH**             133          151        192    132      146      147           150       192
  **FADH**~**2**~       40           47         55     42       48       21            62        55
  **MK**                37           20         11     37       37       20            18        20
  **O**~**2**~          37           76         64     40       41       68            91        65

This analysis indicated that GSMN-TB 1.1, iCG760 and iSM810 models have the lowest number of currency metabolites ([Table 1](#pcbi.1007533.t001){ref-type="table"}). Water and protons were the most underrepresented metabolites (low degree values), indicating that these models may not be correctly balanced. Some GSMNs e.g. iCG760, are functional even in the absence of any currency metabolites however this will negatively affect predictions. It is important that biochemical reactions are charge and mass balanced. Unbalanced reactions in GSMNs may allow proton or ATP production out of nothing \[[@pcbi.1007533.ref040]\]. In order to test whether the Mtb GSMNs are mass and charge balanced, we used the COBRA Toolbox function "checkMassChargeBalance" \[[@pcbi.1007533.ref041]\]. Unfortunately, we were not able to perform this analysis for GSMN-TB1.1, iCG760 and iSM810 due to the lack of standard metabolite formulas in these models ([Table 2](#pcbi.1007533.t002){ref-type="table"}). iEK1011 has the lowest number of unbalanced reactions (4) compared with sMtb2018 (8), sMtb (12), iNJ661v_modified (13) and iOSDD890 (78). The majority of the unbalanced reactions belonged to cell wall biosynthetic pathways, including arabinogalactan, peptidoglycan, and mycolic acid biosynthesis ([S5 Table](#pcbi.1007533.s010){ref-type="supplementary-material"}) reflecting the difficulties in rebuilding accurate metabolite formula for complex cell wall components.

10.1371/journal.pcbi.1007533.t002

###### Global features of the Mtb metabolic models analyzed in this study.

DEM: Dead-End Metabolite, URs: Unbounded Reactions, TICs: Thermodynamically Infeasible Cycles, diss. Flux: dissipation flux, MW: Molecular Weight, UD: Undetermined.
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                                    **GSMN-TB 1.1**   **iOSDD890**   **sMtb**   **iCG760**   **iSM810**   **iNJ661v_mod**   **iEK1011**   **sMtb2018**
  --------------------------------- ----------------- -------------- ---------- ------------ ------------ ----------------- ------------- --------------
  **Reactions**                     876               1152           1311       965          938          1054              1228          1321
  **Intracellular Reactions**       876               1055           1192       864          938          956               1118          1200
  **Metabolites**                   667               961            1047       754          724          840               998           1049
  **DEMs**                          25                162            33         84           53           90                110           34
  **Blocked Reactions**             98 (11%)          290 (25%)      92 (7%)    89 (9%)      117 (12%)    153 (14%)         138 (11%)     92 (7%)
  **Metabolites without Formula**   667               0              2          754          724          0                 4             2
  **Unbalanced Reactions**          UD                78             12         UD           UD           13                4             8
  **URs**                           27 (3%)           52 (5%)        70 (6%)    45 (5%)      33 (3.5%)    67 (7%)           20 (2%)       75 (6%)
  **TICs**                          8                 17             16         8            8            23                4             17
  **ATP diss. Flux**                0                 0              0          0.33         0            0                 0             0
  **GTP diss. Flux**                0                 0              0          0.33         0            0                 0             0
  **CTP diss. Flux**                0                 0              0          0.33         0            0                 0             0
  **UTP diss. Flux**                0                 0              0          0.33         0            0                 0             0
  **Biomass MW**                    UD                1.0070         1.0126     UD           UD           1.0094            1.0937        1.0126

Biomass composition {#sec005}
-------------------

The biomass formulations for the published Mtb GSMNs have been extensively described elsewhere \[[@pcbi.1007533.ref010],[@pcbi.1007533.ref011],[@pcbi.1007533.ref015]\]. The GSMN-TB and iNJ661 models and their respective descendants have different biomass compositions. The biomass composition for GSMN-TB was derived experimentally from chemostat cultures as well as estimated from the literature, whereas iNJ661 biomass was estimated only from literature \[[@pcbi.1007533.ref011],[@pcbi.1007533.ref015]\]. As a result, there are significant differences in the amount of lipid (56% in GSMN-TB versus 25% in iNJ661) and nucleic acids (6% in GSMN-TB and 26% in iNJ661) in the biomass formulations ([S6 Table](#pcbi.1007533.s011){ref-type="supplementary-material"}). Moreover, in order to facilitate modelling of the metabolism of Mtb both *in vitro* and *in vivo*, GSMN-TB has two biomass formulations: "BIOMASS1", containing the complete macromolecular components of Mtb and "BIOMASSe", consisting of only the bacterial components essential for *in vitro* growth.

Growth-associated maintenance and biomass reactions {#sec006}
---------------------------------------------------

The growth-associated maintenance (GAM) is the amount of energy required to replicate the cell whereas the non-growth-associated maintenance (NGAM) \[[@pcbi.1007533.ref015],[@pcbi.1007533.ref032]\] is the amount of ATP required to maintain survival in the absence of growth. For Mtb these values have been estimated using data from other bacteria as experimental data is not available. The Mtb models originating from iNJ661 use a GAM of 60 mmol gDW^-1^; those derived from GSMN-TB have a GAM of 47 mmol gDW^-1^ whilst those originating from sMtb use a GAM of 57 mmol gDW^-1^. The values for NGAM are within the range of 0.1 and 3.15 mmol gDW^-1^ h^-1^ and therefore have negligible effects on gene essentiality predictions \[[@pcbi.1007533.ref032]\].

A comparison between biomass reactions across Mtb GSMNs ([S1 File](#pcbi.1007533.s033){ref-type="supplementary-material"}) showed that the biomass reaction "BiomassGrowthInVitro" from sMtb and sMtb2018 cannot be produced in 7H9 medium containing glycerol, Tween and OADC ([S7 Table](#pcbi.1007533.s012){ref-type="supplementary-material"}). We found this was because sMtb and sMtb2018 are unable to produce spermidine and S-Methyl-5-thio-alpha-D-ribose1-phosphate in these conditions.

Another potential error in GSMNs is the molecular weight of biomass, which should be defined as 1 g/mmol. Discrepancy in biomass weight can arise as a result of unbalanced reactions which will affect the reliability of flux predictions using FBA. This effect can be amplified when host-pathogen interactions are simulated by integrating host and pathogen metabolic models \[[@pcbi.1007533.ref042]\]. Using a systematic algorithm \[[@pcbi.1007533.ref042]\] we found deviations of less than 10% from 1 g/mmol in all the Mtb models tested ([Table 2](#pcbi.1007533.t002){ref-type="table"}) (iOSDD890 (0.7%), iNJ661v_mod (0.9%), sMtb (1.2%), sMtb2018 (1.2%) and iEK1011 (9%)) demonstrating that these models are suitable for modelling the metabolism of Mtb within the host. The biomass of iEK1011 has the highest value because this model is a hybrid of sMtb and the iOSDD890 biomass reactions ([S8 Table](#pcbi.1007533.s013){ref-type="supplementary-material"}).

Blocked reactions and dead-end metabolites {#sec007}
------------------------------------------

Identifying blocked reactions within a GSMN is important for identifying metabolic dead zones caused by dead-end metabolites (metabolites that are not consumed) \[[@pcbi.1007533.ref043]--[@pcbi.1007533.ref045]\]. Using the MC3 algorithm \[[@pcbi.1007533.ref046]\], we show that Mtb models derived from GSMN-TB (GSMN-TB1.1, iCG760, and iSM810) have a smaller number of blocked reactions in comparison with the iNJ661 derived models (iNJ661v_modified, and iOSDD890) ([Table 2](#pcbi.1007533.t002){ref-type="table"}). sMtb and sMtb2018 have the lowest percentage (7%) of blocked reactions, in contrast to iOSDD890, which has the highest percentage (25%). All the Mtb GSMNs included blocked reactions in lipid, cofactor, sugar and amino acid metabolism; iOSDD890, iSM810 and iNJ661v_mod had blockages in important pathways such as glycolysis and redox metabolism ([S9 Table](#pcbi.1007533.s014){ref-type="supplementary-material"}). Most of the models excluding iCG760 and iSM810 contained gaps in the vitamin B12 biosynthesis pathway \[[@pcbi.1007533.ref047]\]. Specifically, we found that aqua(III) cobalamin and different cobalt-precorrins were not connected by reactions in most of the networks. This cofactor is necessary for activation of essential pathways such as nucleotide, propionate, and amino acids metabolism \[[@pcbi.1007533.ref047]\]. The existence of a functional B12 biosynthetic pathway is still under debate. A bona-fide transporter of vitamin B12 has been identified \[[@pcbi.1007533.ref048],[@pcbi.1007533.ref049]\], however there remains no direct evidence that Mtb is able to scavenge vitamin B12 from its intracellular niche \[[@pcbi.1007533.ref049],[@pcbi.1007533.ref050]\].

Of those models that contained a pathway for cholesterol degradation (GSMN-TB1.1, iCG760, iSM810, iEK1011, sMtb, and sMtb2018) the GSMN-TB1.1 cholesterol degrading pathway contained a number of dead end metabolites making this model unsuitable for exploring the metabolism of this important *in vivo* carbon source.

Thermodynamic and energetic properties {#sec008}
--------------------------------------

Integrating thermodynamics data into GSMNs is extremely useful in order to check the feasibility of reactions and their directionality \[[@pcbi.1007533.ref051],[@pcbi.1007533.ref052]\]. Although, Mtb GSMNs have been built from thermodynamics information, current Mtb GSMNs have never been checked for infeasible internal flux cycles. These are reactions that do not exchange metabolites with the surroundings and therefore violate the second law of thermodynamics \[[@pcbi.1007533.ref051],[@pcbi.1007533.ref053],[@pcbi.1007533.ref054]\]. A tractable way to identify reactions participating in these thermodynamically infeasible cycles (TICs) is to define the set of reactions required for an unbounded metabolic flux under finite or zero substrate uptake inputs. Using FVA the Unbounded Reactions (URs) can be identified as those reactions with fluxes at the upper and/or lower bound constraints. Thus we identified the thermodynamically infeasible cycles (TIC) using a local script following methodologies based on FVA and the analysis of the null space of the stoichiometric matrices ([S10 Table](#pcbi.1007533.s015){ref-type="supplementary-material"}, [S2 File](#pcbi.1007533.s034){ref-type="supplementary-material"}) \[[@pcbi.1007533.ref052],[@pcbi.1007533.ref055]\]. Using this approach we show that models descended from GSMN-TB (GSMN-TB1.1, iCG760, and iSM810) have a lower percentage of unbounded reactions as compared with iNJ661 ancestors (iSM810, iNJ661v_modified). Interestingly, the sMtb2018 model has an increased number of unbounded reactions as compared to the original sMtb ([Table 2](#pcbi.1007533.t002){ref-type="table"}).

Fritzemeier and colleagues demonstrated that over 85% of genome-scale models that lack exhaustive manual curation contain Energy Generating Cycles (EGCs) \[[@pcbi.1007533.ref056],[@pcbi.1007533.ref057]\]. These cyclic net fluxes are entirely independent of nutrient uptakes (exchange fluxes) and therefore have a substantial effect on the predictions of constraint-based analyses, as they basically generate energy out of nothing. Using FBA with zero nutrient uptake \[[@pcbi.1007533.ref057]\] but maximizing energy dissipation reactions for ATP, GTP, CTP and UTP we show that iCG760 is the only Mtb genome-scale model that contains EGCs ([Table 2](#pcbi.1007533.t002){ref-type="table"}).

Gene essentiality metrics {#sec009}
-------------------------

An effective and commonly employed predictive matrix for GSMNs is the ability to reproduce high throughput gene essentiality data \[[@pcbi.1007533.ref058]\]. Several high throughput transposon mutagenesis screens have been performed for Mtb \[[@pcbi.1007533.ref059]--[@pcbi.1007533.ref065]\] in different *in vitro* conditions. To compare our models we used a transposon insertion sequence dataset produced by Griffin *et al* \[[@pcbi.1007533.ref062]\]. In this study genes were identified that were essential for growth on cholesterol as compared with glycerol \[[@pcbi.1007533.ref062]\]. Cholesterol is an important intracellular source of carbon when Mtb is growing within its host and cholesterol metabolism has been highlighted as a potential drug target \[[@pcbi.1007533.ref066]\]. This data was not, however used to identify the genes required for growth on cholesterol only. We therefore reanalyzed the Griffin transposon sequencing data using the statistical Bayesian/Gumbel Method incorporated into the software TRANSIT \[[@pcbi.1007533.ref067]\], to identify genes required for growth on glycerol, or growth on cholesterol ([S11](#pcbi.1007533.s016){ref-type="supplementary-material"} and [S12](#pcbi.1007533.s017){ref-type="supplementary-material"} Tables). Only genes categorized as essential (ES) and non-essential (NE) were considered for this analysis.

We evaluated the overall predictive power of all the Mtb GSMNs versus a total of four high throughput gene essentiality datasets \[[@pcbi.1007533.ref062],[@pcbi.1007533.ref064],[@pcbi.1007533.ref065]\] by computing the Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) ([S1 Fig](#pcbi.1007533.s004){ref-type="supplementary-material"}). The predictive power of the six GSMNs that contain the cholesterol degradation pathway (GSMN-TB1.1, iCG760, iSM810, sMtb, sMtb2018 and iEK1011) showed that for both cholesterol and glycerol minimal media the models derived from GSMN-TB \[[@pcbi.1007533.ref010]\] as a core metabolic network have better predictive capacities than those using iNJ661 \[[@pcbi.1007533.ref011]\] ([S13](#pcbi.1007533.s018){ref-type="supplementary-material"} and [S14](#pcbi.1007533.s019){ref-type="supplementary-material"} Tables). However the recently curated model iEK1011 had the highest predictive capability overall. The supremacy of iEK1011 was also confirmed by comparing the predictive power of the models using essentiality data obtained for Mtb grown in standard Middlebrook 7H9 media \[[@pcbi.1007533.ref064]\] ([S1C Fig](#pcbi.1007533.s006){ref-type="supplementary-material"} and [S15 Table](#pcbi.1007533.s020){ref-type="supplementary-material"}).

We also used the essentiality dataset generated by Minato and colleagues who identified conditionally essential Mtb genes using several *in vitro* conditions including a complex medium "MtbYM", which contains several carbon and nitrogen sources and also amino acids, nucleotide bases, cofactors, and other nutrients \[[@pcbi.1007533.ref065]\]. Overall the Mtb GSMN were less able to correctly predict essentiality ([S1D Fig](#pcbi.1007533.s006){ref-type="supplementary-material"} and [S16 Table](#pcbi.1007533.s021){ref-type="supplementary-material"}) in MtbYM as compared to other media ([S1A--S1C Fig](#pcbi.1007533.s004){ref-type="supplementary-material"}), probably because the biomass objective functions were reconstructed and validated using growth on standard Mtb media \[[@pcbi.1007533.ref010],[@pcbi.1007533.ref011]\]. However these analyses demonstrated the ability of these models to accurately predict gene essentiality under new nutritional conditions.

We identified genes that all of the GSMN's were unable to correctly assign essentiality ([S17 Table](#pcbi.1007533.s022){ref-type="supplementary-material"}, [Fig 3](#pcbi.1007533.g003){ref-type="fig"}). Using a fixed threshold value of 5% of the maximum wild-type growth rate (WTGR) we identified *in silico* essential and non-essential genes and compared these to the experimental high throughput gene essentiality data to identify True Positives (TP), True Negatives (TN), False Positives (FP-a gene which is essential for *in silico* growth but non-essential by Tn-seq) and False Negatives (FN-*in silico* the gene is non-essential but the biological data predicts essentiality). The FN included genes known to have a major role in Mtb central carbon metabolism e.g., *icl* (Rv0467, isocitrate lyase), *glt*A (Rv0896, Citrate synthase), *glp*D2 (Rv3302c, Glycerol-3-phosphate dehydrogenase), *pyk* (Rv1617, Pyruvate Kinase), *suc*C and *suc*D (Rv0951, Rv0952, Succinyl-CoA ligase), among others ([S17A Table](#pcbi.1007533.s022){ref-type="supplementary-material"}). Some of these genes e.g. *icl* and *glt*A are considered conditionally essential genes in the Online GEne Essentiality (OGEE) database \[[@pcbi.1007533.ref068]\], because they are classified as NE genes in 7H10 medium but ES in minimal medium \[[@pcbi.1007533.ref061],[@pcbi.1007533.ref063]\]. This may reflect the presence of alternative routes *in silico* that are not feasible *in vivo* due to regulatory constraints. However, they may also reflect inaccuracies in the transposon mutagenesis studies. Some of the FP genes are involved in mycolic acid biosynthesis ([S17B Table](#pcbi.1007533.s022){ref-type="supplementary-material"}), e.g., *mma*A2 (Rv0644c, Cyclopropane mycolic acid synthase), and *mas* (Rv2940c, mycocerosic acid synthase). These genes were inaccurately classified as ES *in silico* but experimentally as NE. This reflects our incomplete knowledge of Mtb requirements for different mycolates and mycolate anabolism.

![False Negative and False Positive predictions in the evaluated media.\
(a) Venn diagram for predicted false negative (FN) genes; (b) Venn diagram for predicted false positive (FP) genes. Genes in the grey box represents the intersection of all FN and FP genes in the four media. Genes are classified as True-positives (TP) if model simulation predicts no growth when essential genes are deleted, False-positives (FP) if model simulation predicts no growth when not essential genes are deleted, True negatives (TN) if model simulation predicts growth when not essential genes are deleted and False negatives (FN) if model simulation predicts growth when essential genes are deleted.](pcbi.1007533.g003){#pcbi.1007533.g003}

Growth metrics {#sec010}
--------------

Mtb is able to metabolise several carbon and nitrogen sources both *in vitro* and when growing in the host \[[@pcbi.1007533.ref028],[@pcbi.1007533.ref069]--[@pcbi.1007533.ref071]\], and therefore we evaluated the growth metrics of Mtb GSMNs on 30 sole carbon and 17 sole nitrogen sources ([Fig 4](#pcbi.1007533.g004){ref-type="fig"}). The *in silico* results were compared with available experimental data from Biolog Phenotype microarrays and minimal media \[[@pcbi.1007533.ref014],[@pcbi.1007533.ref072]\]. Interestingly the recent consolidated models, iEK1011 and sMtb, had the poorest performance of all the models in predicting growth of Mtb in unique carbon and nitrogen sources ([Fig 4A and 4B](#pcbi.1007533.g004){ref-type="fig"}). A fundamental issue with the Mtb models descended from iNJ661 is that they all require glycerol for growth as this is a component of the biomass formulation. Both iEK1011 and sMtb were unable to grow *in silico* on cholesterol, acetate, oleate, palmitate and propionate when provided as sole carbon sources. We posit that this is a result of inaccuracies in reactions associated with redox metabolism and oxidative phosphorylation and specifically menaquinone-dependent reactions such as fumarate reductase and succinate dehydrogenase \[[@pcbi.1007533.ref073]--[@pcbi.1007533.ref076]\]. To test this hypothesis we added an irreversible menaquinone-dependent succinate dehydrogenase reaction into sMtb (Q\[c\] + SUCC\[c\] -\> QH2\[c\] + FUM\[c\]). In support of our hypothesis this corrected the *in silico* growth phenotype of Mtb growing on acetate, cholesterol, propionate and fatty acids ([Fig 4A](#pcbi.1007533.g004){ref-type="fig"} and [S18 Table](#pcbi.1007533.s023){ref-type="supplementary-material"}). Although iEK1011 also contains a fumarate reductase reaction that is linked to menaquinone/demethylmenaquinone, it does not contain a menoquinone-dependent succinate dehydrogenase (the reverse reaction). As was the case for sMtb, the addition of a new irreversible menaquinone-dependent succinate dehydrogenase reaction (mqn8\[c\] + succ\[c\] -\> fum\[c\] + mql8\[c\]) to iEK1011 significantly improves its growth predictions on sole carbon sources ([S18I and S18J Table](#pcbi.1007533.s023){ref-type="supplementary-material"}). These simulations are supported by experimental data demonstrating that fumarate reductase and succinate dehydrogenase are essential for Mtb to grow in media containing glycolytic and non-glycolytic substrates \[[@pcbi.1007533.ref074],[@pcbi.1007533.ref075]\]. Succinate dehydrogenase is a bifunctional enzyme that is part of the TCA cycle and complex II of the electron transport chain, coupling the oxidation of succinate to fumarate, with the corresponding reduction of membrane-localized quinone electron carriers \[[@pcbi.1007533.ref075],[@pcbi.1007533.ref077]\]. Mtb has multiple succinate dehydrogenases and fumarate reductases that are essential for the survival of Mtb during hypoxia \[[@pcbi.1007533.ref073]--[@pcbi.1007533.ref075],[@pcbi.1007533.ref078],[@pcbi.1007533.ref079]\]. Succinate is central to much of Mtb's lipid metabolism: host derived cholesterol, uneven chain length fatty acids or methyl branched amino acids all generate propionyl-CoA that can be channeled into the methylcitrate cycle to produce succinate ([S2 Fig](#pcbi.1007533.s005){ref-type="supplementary-material"}), while acetyl-CoA produced by β-oxidation of host derived even-chain fatty acids is metabolized through the glyoxylate shunt to also produce succinate ([S2 Fig](#pcbi.1007533.s005){ref-type="supplementary-material"}). Succinate oxidation by succinate dehydrogenases is therefore a critical step, as the enzyme couples the TCA cycle with electron transport chain and oxidative phosphorylation \[[@pcbi.1007533.ref078]\]. Having multiple succinate dehydrogenases provides Mtb with the metabolic flexibility to survive within the different niches within the human host.

![Predictive capacity of Mtb genome-scale models for the utilization of sole carbon and nitrogen sources; **(a)** Growth predictions of Mtb genome-scale models using sole carbon sources; **(b)** Growth predictions of Mtb genome-scale models by using sole nitrogen sources. Model's performance was evaluated by computation of the Matthews Correlation Coefficient (MCC). Experimental growth data were obtained from \[[@pcbi.1007533.ref014],[@pcbi.1007533.ref072]\]. The values represent growth (value = 1) and no growth (value = 0) in a specific substrate, respectively. Carbon or Nitrogen substrates are classified as TP if the model predicts growth and growth is also observed experimentally, FP if the model predicts growth but no growth is observed experimentally, TN if the model and the experimental data both predict no growth and FN if model simulation predicts no growth but growth is observed experimentally.](pcbi.1007533.g004){#pcbi.1007533.g004}

Whilst carbon metabolism has been intensively studied *in vitro* and *ex vivo*, attention has only recently been directed to nitrogen metabolism \[[@pcbi.1007533.ref080]--[@pcbi.1007533.ref083]\]. Similar to carbon consumption, iEK1011 and sMtb were poor at predicting Mtb growth on sole nitrogen sources ([Fig 4B](#pcbi.1007533.g004){ref-type="fig"}, Matthews Correlation Coefficient (MCC) = 0.54 and 0.48, respectively). However, like carbon the addition of the menaquinone linked succinate dehydrogenase reaction into iEK1011 and sMtb significantly improves *in silico* growth on sole nitrogen sources ([S19I and S19J Table](#pcbi.1007533.s024){ref-type="supplementary-material"}). Specifically, correct growth predictions were obtained for Mtb growing on branched chain amino acids (isoleucine and valine) and proline ([Fig 4B](#pcbi.1007533.g004){ref-type="fig"}). This can be explained because complete degradation of these amino acids converges on succinate via methyl citrate cycle (degradation of isoleucine and valine) or the GABA shunt (degradation of proline) thereby coupling the TCA cycle with oxidative phosphorylation via succinate dehydrogenase.

Refining Mtb GSMNs {#sec011}
------------------

Overall iEK1011 and sMtb2018 were the best GSMN's in terms of genetic background, network topology, number of blocked reactions, mass and charge balance reactions and gene essentiality predictions ([Fig 2](#pcbi.1007533.g002){ref-type="fig"}, [Table 1](#pcbi.1007533.t001){ref-type="table"}, [Table 2](#pcbi.1007533.t002){ref-type="table"}, and [S1 Fig](#pcbi.1007533.s004){ref-type="supplementary-material"}) and therefore we selected these models to refine further. iEK1011 has the advantage of containing standardized BiGG nomenclature of metabolites and therefore can easily be integrated into the human GSMN Recon3D \[[@pcbi.1007533.ref084]\] to simulate intracellular growth, while sMtb2018 has the utility that this model supports *in silico* growth in a wider variety of different nutritional conditions. Our analysis also highlighted some fundemental issues with these models which we analysed in order to improve the performance of these exemplar GSMN's.

As discussed above, including menaquinone and menaquinol as electron carriers in all respiratory chain reactions and selected ubiquinone-dependent reactions improved the GSMN's. Six new menaquinone-dependent reactions were added into the sMtb model e.g., succinate dehydrogenase, and cytochrome bc1 menaquinone-dependent, fumarate reductase, and malate dehydrogenase \[[@pcbi.1007533.ref030]\]. This improved the predictive growth metric of sMtb and importantly allowed *in silico* growth on cholesterol (see sMtb2018, [Fig 4A](#pcbi.1007533.g004){ref-type="fig"}). Similarly, we added to iEK1011 an irreversible menaquinone-dependent succinate dehydrogenase to improve the performance of this model when growing on media containing fatty acids and cholesterol. Further improvements were also made to cholesterol metabolism by updating both models to include reactions for the biochemical degradation of the C and D rings of cholesterol which was not known when these models were reconstructed ([S20A and S20B Table](#pcbi.1007533.s025){ref-type="supplementary-material"}) \[[@pcbi.1007533.ref085]\].

Although the functionality of a vitamin B12 biosynthetic pathway in Mtb remains uncertain, the detection of a small ratio of non-synonymous (dN) and synonymous (dS) nucleotide substitution (dN/dS \< 1) in the cobalamin biosynthesis genes of clinical strains of Mtb suggests that this bacteria may be able to synthesize B12 in certain conditions \[[@pcbi.1007533.ref050]\]. Therefore, until there is further experimental evidence to the contrary, we completed a B12 biosynthesis pathway by adding the genes Rv0306 and *cobCDU* to the models as well a B12 transporter (*Rv1819c and Rv1314c*), and added a dependence for B12 to MUTA (Methylmalonyl CoA Mutase) and METH (Methionine Synthase) reactions. We also included the co-factors biotin and pyridoxal-5-phosphate in the biomass formulation to enhance the phenotype prediction of sMtb2018 and iEK1011 as recommended by Xavier *et al*. \[[@pcbi.1007533.ref019]\].

Using the iNJ661v_modified model Xavier and colleagues demonstrated that inclusion of essential organic cofactors in biomass objective function improves phenotypic and gene essentiality predictions \[[@pcbi.1007533.ref019]\]. Here, the biomass reaction from iEK1011 was improved by the addition of universal cofactors such as sodium, NAD, NADP, CoA, FAD, FMN, Pyridoxal-5-phosphate, thiamine pyrophosphate, tetrahydrofolate, 5-formyltetrahydrofolate etc. to generate a new biomass formulation called "BIOMASS\_\_2.1" ([S20B Table](#pcbi.1007533.s025){ref-type="supplementary-material"}). This biomass formula does not contain glycerol and therefore allowed this model, like Mtb itself, to grow in media lacking this carbon source. Similarly, we modified the biomass formula of sMtb to create "BiomassGrowth_2.0" which we incorporated into sMtb2.0.

We also added 51 missing genes into sMtb2018 that were identified from the iOSDD890 model and belong to pathways such as glycolysis, gluconeogenesis, TCA cycle, amino acid metabolism and mycolic acid biosynthesis to improve the GPR and predictive accuracy of this model ([S21 Table](#pcbi.1007533.s026){ref-type="supplementary-material"}).

We also identified (see [method](#sec014){ref-type="sec"} section) ([S22 Table](#pcbi.1007533.s027){ref-type="supplementary-material"}) \[[@pcbi.1007533.ref052],[@pcbi.1007533.ref055]\] twelve TICs within sMtb2.0; ([Fig 5A](#pcbi.1007533.g005){ref-type="fig"}, [S2 Appendix](#pcbi.1007533.s002){ref-type="supplementary-material"}) and seven TICs in iEK1011_2.0 ([Fig 5B](#pcbi.1007533.g005){ref-type="fig"}, [S3 Appendix](#pcbi.1007533.s003){ref-type="supplementary-material"}); The major TIC of sMtb2.0 were within folate metabolism, catalysed by thymidylate synthase (thyA and thyX) and dihydrofolate reductase (DFRA). These reactions areessential steps for *de novo* glycine and purine biosynthesis and for the conversion of deoxyuridine monophosphate (dUMP) to deoxytimidine monophosphate (dTMP) ([Fig 5A](#pcbi.1007533.g005){ref-type="fig"}). DFRA 1 and DFRA 2, and DFRA 3 and DFRA4 are parallel reactions catalyzed by Rv2763c, dihydrofolate dehydrogenase. These reactions are identical except that they use a different currency metabolite ([Fig 5A](#pcbi.1007533.g005){ref-type="fig"}). Pereira and colleagues \[[@pcbi.1007533.ref038]\] recommend the use of NADPH/NADP in anabolic reactions and NADH/NAD^+^ in catabolic reactions for more accurate flux distributions. Therefore we modified the model by retaining the DFRA2 and DFRA4 reactions and eliminating the NADH/NAD^+^-dependent reactions, DFRA1 and DFRA3. Our thermodynamic calculations indicate that THYA and THYX (Δ~*r*~*G*~*min*~ = -123 kJ/mol, Δ~*r*~*G*~*max*~ = -9.3 kJ/mol and Δ~*r*~*G*~*min*~ = -160 kJ/mol, Δ~*r*~*G*~*max*~ = -33 kJ/mol, respectively) are irreversible in the forward direction ([S23 Table](#pcbi.1007533.s028){ref-type="supplementary-material"}) and therefore we also modified these reactions accordingly.

![Thermodynamic Infeasible Cycles found in sMtb2.0 and iEK1011_2.0 with proposed modifications; **(a)** TIC at folate metabolism in sMtb2.0; **(b)** TIC affecting ubiquinone oxidoreductases in iEK1011_2.0.](pcbi.1007533.g005){#pcbi.1007533.g005}

Our analysis also showed that two-ubiquinone oxidoreductases (QRr, NADH2r) and a transhydrogenase reaction (NADTRHD) were thermodynamically infeasible within the iEK1011_2 as both were identified as reversible. The Gibbs free energy computations indicate that these reactions are unidirectional in the direction of ubiquinol production ($\Delta_{r}G_{min} = - 134.9\frac{kJ}{mol},\ \Delta_{r}G_{max} = - 20.7\ kJ/mol$ and $\Delta_{r}G_{min} = - 131.7\frac{kJ}{mol},\ \Delta_{r}G_{max} = - 20.1\ kJ/mol$, respectively) and therefore we changed the model accordingly.

The modified model Mtb2.0 consists of 1322 reactions, 1054 metabolites and 989 genes, while iEK1011_2.0 comprises of 1238 reactions, 977 metabolites and 1012 genes. The predictive capability of these models was then evaluated by simulating gene essentiality predictions using available high-throughput essentiality experimental data \[[@pcbi.1007533.ref062],[@pcbi.1007533.ref064],[@pcbi.1007533.ref065]\] defining 5% of the wild-type growth rate as our arbitary essentiality threshold ([S24 Table](#pcbi.1007533.s029){ref-type="supplementary-material"}). This analysis showed that iEK1011_2.0 has the highest predictive performance in the four media conditions tested (glycerol and cholesterol minimal medium, Middlebrook 7H9, and YM medium) compared with all the Mtb GSMNs evaluated, including sMtb2.0 ([Table 3](#pcbi.1007533.t003){ref-type="table"}). The ability of these updated models to predict growth on sole carbon and nitrogen sources was also improved ([S25 Table](#pcbi.1007533.s030){ref-type="supplementary-material"}). This included important carbon sources available in the human host and therefore iEK1011_2.0 and sMtb2.0 are suitable models for studying host-pathogen interactions \[[@pcbi.1007533.ref028]\].

10.1371/journal.pcbi.1007533.t003

###### Genome-scale model features for sMtb2.0 and iEK1011_2.0.

![](pcbi.1007533.t003){#pcbi.1007533.t003g}

  Metrics                              sMtb2.0     iEK1011_2.0
  ------------------------------------ ----------- -------------
  **Genes**                            989         1012
  **Reactions**                        1322        1238
  **Intracellular Reactions**          1198        1119
  **Exchange Reactions**               122         119
  **Metabolites**                      1054        977
  **% of Unbounded Reactions**         \(49\) 4%   20 (1.8%)
  **MCC Cholesterol minimal medium**   **0.55**    **0.63**
  **Evaluated Genes**                  834         866
  True Positive Genes                  209         210
  True Negative Genes                  449         503
  False Positive Genes                 58          21
  False Negative Genes                 118         132
  **MCC Glycerol minimal medium**      **0.54**    **0.62**
  **Evaluated Genes**                  834         866
  True Positive Genes                  207         206
  True Negative Genes                  449         503
  False Positive Genes                 58          21
  False Negative Genes                 120         136
  **MCC 7H9 medium**                   **0.56**    **0.69**
  **Evaluated Genes**                  984         1006
  True Positive Genes                  202         216
  True Negative Genes                  600         667
  False Positive Genes                 96          45
  False Negative Genes                 86          78
  **MCC MtbYM medium**                 **0.43**    **0.52**
  **Evaluated Genes**                  827         858
  True Positive Genes                  153         152
  True Negative Genes                  458         509
  False Positive Genes                 51          17
  False Negative Genes                 165         180
  **MCC Unique Carbon Source**         **0.58**    **0.67**
  **Evaluated Metabolites**            30          30
  True Positive Metabolites            20          20
  True Negative Metabolites            5           6
  False Positive Metabolites           4           3
  False Negative Metabolites           1           1
  **MCC Unique Nitrogen Source**       **0.75**    **0.75**
  **Evaluated Metabolites**            17          17
  True Positive Metabolites            11          11
  True Negative Metabolites            4           4
  False Positive Metabolites           2           2
  False Negative Metabolites           0           0

The models iEK1011_2.0 and sMtb2.0 were then evaluated using MEMOTE \[[@pcbi.1007533.ref086]\], which is a standardised approach to quality control metabolic models. Overall scores for iEK1011_2.0 and sMtb2.0 were 74% and 37%, respectively ([S3 File](#pcbi.1007533.s035){ref-type="supplementary-material"}). The poor score for sMtb2.0 is misleading: it results from the lack of standardised nomencalature and does not reflect the model's accuracy. Indeed the scores for the consistency category were 64% and 80%, for iEK1011_2.0 and sMtb2.0, respectively, demonstrating their high quality and utility in systems biology applications.

Pathway utilization of sMtb2.0 and iEK1011_2.0 {#sec012}
----------------------------------------------

Using Roisin's Minimal Media containing glycerol and Tween80 (represented by oleic acid in the Mtb models) \[[@pcbi.1007533.ref070]\], we carried out Flux Variability Analysis (FVA) \[[@pcbi.1007533.ref087]\], FBA and uniform sampling using sMtb2.0 and iEK1011_2.0. FVA is a variant of FBA which, instead of finding a single optimal solution, computes the range of fluxes in each reaction that are compatible with optimization of the objective function \[[@pcbi.1007533.ref087],[@pcbi.1007533.ref088]\]. A GAM value of 1 mmol gDW^-1^ h^-1^ and experimental uptake rates (glycerol, oleic acid and CO~2~) from steady state chemostat cultures at a growth rate of 0.01 h^-1^ \[[@pcbi.1007533.ref089]\] were used as constraints in both models. Complete results are reported in ([S26A and S26B Table](#pcbi.1007533.s031){ref-type="supplementary-material"}), but for brevity we discuss only the 33 reactions of Central Carbon Metabolism (CCM) and 21 extracellular (EX) reactions ([S26C Table](#pcbi.1007533.s031){ref-type="supplementary-material"}, [S4 File](#pcbi.1007533.s036){ref-type="supplementary-material"}) as informative examples. FBA using iEK1011_2.0 and sMtb2.0 predicts growth rates of 0.0084 h^-1^ and 0.025 h^-1^, respectively ([S26C Table](#pcbi.1007533.s031){ref-type="supplementary-material"}) showing that iEK1011_2.0 more accurately predicts experimental Mtb growth rate under these conditions \[[@pcbi.1007533.ref089]\].

Our FVA results showed that there were significant differences in the flux ranges when using the two models (p \< 0.001; Kruskal-Wallis test). We hypothesized that this was a result of the different biomass formulations in the two models. In order to test this hypothesis we performed FVA without constraining the biomass objective function and in accordance with our expectations these simulations generated similar flux profiles ([S27 Table](#pcbi.1007533.s032){ref-type="supplementary-material"}, [S4](#pcbi.1007533.s036){ref-type="supplementary-material"} File).

A comparison of the FVA results with the experimental ^13^C-Metabolic Flux profiles of chemostat grown Mtb indicates that the models are able to correctly predict the general experimental metabolic flux profile \[[@pcbi.1007533.ref089]\]. For instance, although sMtb2.0 has a higher flux distribution through gluconeogenic enzymes such as FBA and FBP compared to iEK1011_2.0 ([Fig 6](#pcbi.1007533.g006){ref-type="fig"} and [S26 Table](#pcbi.1007533.s031){ref-type="supplementary-material"}), both values are comparable with the experimental flux values \[[@pcbi.1007533.ref089]\]. Flux through the non-oxidative enzymes of the pentose phosphate pathway enzymes, TKT and TAL, was greater in sMtb2.0 than in iEK1011_2.0 ([Fig 6](#pcbi.1007533.g006){ref-type="fig"} and [S26 Table](#pcbi.1007533.s031){ref-type="supplementary-material"}) and the oxidative phase of the pentose phosphate pathway wasn't active in either of the models ([Fig 6](#pcbi.1007533.g006){ref-type="fig"} and [S26 Table](#pcbi.1007533.s031){ref-type="supplementary-material"}).

![Flux Sampling and FVA bounds of CCM reactions of sMtb2.0 and iEK1011_2.0 under Roisin\'s media and default biomass objective function.\
The x-axis represents Flux values in mmol gDW^-1^ h^-1^. Dashed lines represent FVA bounds. Solid lines represent Flux sampling distributions. Reactions for which the two distributions are significantly different (p \< 0.001; Kruskal--Wallis test) are marked with an asterisk in the top right corner. GLYK (Glycerol kinase), PGM (Phosphoglycerate mutase), PYK (Pyruvate kinase), PCKA (Phosphoenolpyruvate carboxykinase), CS (Citrate synthase), SDH (Succinate dehydrogenase), FUM (Fumarase), ATPS (ATP synthase), ZWF (Glucose 6-phosphate dehydrogenase), TKT (Transketolase), TAL (Transaldolase), ICL (Isocitrate Lyase), KGD (2-oxoglutarate dehydrogenase), FBA (Fructose-biphosphate aldolase), FBP (Fructose biphosphatase), ICD (Isocitrate dehydrogenase), SUCOAS (Succinyl CoA synthetase).](pcbi.1007533.g006){#pcbi.1007533.g006}

Flux through the TCA cycle was slightly different between the two models however the general pattern was similar to the experimentally derived fluxes ([S26 Table](#pcbi.1007533.s031){ref-type="supplementary-material"}). sMtb2.0 predicted a lower carbon flux though the oxidative side of the TCA cycle than iEK1011_2.0 ([Fig 6](#pcbi.1007533.g006){ref-type="fig"}, [S26 Table](#pcbi.1007533.s031){ref-type="supplementary-material"}) and therefore was more aligned with the experimental data. Both models correctly predicted an active glyoxylate shunt and oxidation of pyruvate via the carbon fixing anaplerotic reaction, PCK, to produce oxaloacetate and succinyl-CoA through succinyl-CoA synthetase ([Fig 6](#pcbi.1007533.g006){ref-type="fig"}, and [S26C Table](#pcbi.1007533.s031){ref-type="supplementary-material"}). However, iEK1011_2.0 incorrectly predicts that this enzyme is functioning in the reverse direction producing succinate ([S26C Table](#pcbi.1007533.s031){ref-type="supplementary-material"}). Overall both models show utility in predicting experimental metabolic fluxes.

Conclusions {#sec013}
-----------

By systematically evaluating eight of the recent Mtb GSMNs, we have highlighted the advantages and flaws of each of the models and identified solutions to some of their shortcomings. Importantly we have highlighted that the Mtb models descended from GSMN-TB (GSMN-TB1.1, iSM810 and iCG760) contain many unbalanced reactions, often because protons and water have not been accounted for. Dead-end metabolites, particularly in cofactor metabolism and related pathways was also an issue for some of the GSMNs. Overall, we show that sMtb2018 and iEK1011 have the best predictive power for Mtb. This analysis allowed us to update these two models by the addition of new reactions, gap filling of cofactor metabolism, and the identification and curation of TICs, to generate Mtb models with increased veracity.

The improved GSMN's, sMtb2.0 and iEK1011_2.0, with their respective Memote report \[[@pcbi.1007533.ref086]\], are now available in sbml and json formats ([S3](#pcbi.1007533.s035){ref-type="supplementary-material"} and [S5 Files](#pcbi.1007533.s037){ref-type="supplementary-material"}) to simulate and predict the metabolic adaptation of Mtb in a plethora of *in vitro* and *in vivo* intracellular conditions. We encourage researchers to continue to curate these models as new data and methods become available. Improved GSMN's including macrophage-Mtb models provide a critical platform for increasingly more accurate simulations and ultimately a better understanding of the underlying biology of this pathogen.

Methods {#sec014}
=======

All simulations were conducted on a laptop running Windows 10 (Microsoft) using MATLAB 2016a (MathWorks Corporation, Natick, Massachusetts, USA), COBRA Toolbox version 3.0 \[[@pcbi.1007533.ref041]\], RAVEN 2.0 \[[@pcbi.1007533.ref090]\] and Gurobi Optimizer version 7.5.2 (Gurobi Optimization, Inc., Houston, Texas, USA). All code written for this study is available in supplementary information ([S1](#pcbi.1007533.s033){ref-type="supplementary-material"}--[S8 Files](#pcbi.1007533.s040){ref-type="supplementary-material"}). Genome-scale models of Mtb Models were obtained from supplementary information of published papers and modified as follows:

-   GSMN-TB1.1 --from \[[@pcbi.1007533.ref014]\] supplementary info.

-   iOSDD890 --from \[[@pcbi.1007533.ref016]\] supplementary info.

-   sMtb--from \[[@pcbi.1007533.ref015]\] supplementary info. Modification included were the addition of exchange reactions to allow constraints by growth medium components.

-   iCG760 --from \[[@pcbi.1007533.ref017]\] supplementary info.

-   iSM810 --from \[[@pcbi.1007533.ref018]\] supplementary info.

-   iNJ661v_modified--from \[[@pcbi.1007533.ref019]\] supplementary info.

-   sMtb2018 --from \[[@pcbi.1007533.ref030]\] supplementary info.

-   iEK1011 --from \[[@pcbi.1007533.ref032]\] supplementary info.

Network connectivity evaluation {#sec015}
-------------------------------

GSMNs of Mtb were transformed to substrate networks by local scripts after eliminating biomass reaction. Node-specific topology metrics were carried out using the plugin Network Analyzer \[[@pcbi.1007533.ref091]\] in Cytoscape 3.4 \[[@pcbi.1007533.ref092]\]. Two main topological parameters were evaluated for each model: 1) the node degree of each metabolite and 2) the clustering coefficient ([S4 Table](#pcbi.1007533.s009){ref-type="supplementary-material"}).

MC3 Consistency Checker algorithm \[[@pcbi.1007533.ref046]\] was used to identify Single Connected and Dead End metabolites, and zero-flux reactions in each metabolic network model of Mtb. This algorithm uses a stoichiometric-based identification of metabolites connected only once in each metabolic network and utilize Flux-Variability-Analysis (FVA) for identifying reactions that cannot carry flux \[[@pcbi.1007533.ref087]\].

Biomass Molecular Weight Check {#sec016}
------------------------------

Testing the biomass Molecular Weight consistency was done by running the script of Chan and colleagues \[[@pcbi.1007533.ref042]\]. A biomass reaction is not standardized when the Molecular Weight of the biomass formula is not equal to 1 g/mmol. However, the accuracy of the results relies on the correct chemical formulae of metabolites in the tested GSMNs. Furthermore, we check charge and mass balance of all Mtb GSMNs ([S6 File](#pcbi.1007533.s038){ref-type="supplementary-material"}).

Identification of Unbounded Reactions (URs) {#sec017}
-------------------------------------------

A straightforward way to identify all reactions that participate in one or more TICs is by performing flux variability analysis (FVA). All the Infeasible loops are evidenced as a set of reactions able to carry an unbounded metabolic flux under finite or even zero substrate uptake inputs. The URs are those reactions that by applying FVA \[[@pcbi.1007533.ref087]\], their fluxes will hit the values defined by the upper and/or lower bounds constraints \[[@pcbi.1007533.ref055]\]. Therefore, we performed FVA with the eight Mtb GSMNs with all the uptake media constraints defined by 1.0 mmol/gDW/h ([S2 File](#pcbi.1007533.s034){ref-type="supplementary-material"}).

Identification of the core set of TICs {#sec018}
--------------------------------------

Schellenberger and colleagues \[[@pcbi.1007533.ref093]\] used a methodology for identifying the core set of TICs, which form the basis of all such possible cycles. This core set can be obtained by the computation of the null space basis of the stoichiometric matrix (all possible thermodynamically infeasible cycles form the null space of the stoichiometric matrix). Consequently, the set containing all the reactions that we previously identified participate in TICs was used to build a stoichiometric matrix. Therefore, the null space basis of this set was computed and the different cycles composed by two and more reactions were identified by a local script ([S2 File](#pcbi.1007533.s034){ref-type="supplementary-material"}).

Checking the existence of Energy Generating Cycles (EGCs) {#sec019}
---------------------------------------------------------

Energy generating cycles (EGCs) exist in metabolic networks and can charge energy metabolites like ATP, GTP, CDP, and UTP without any input of nutrients; therefore, their elimination is essential for correcting energy metabolism \[[@pcbi.1007533.ref057],[@pcbi.1007533.ref094]\]. Fritzemeier and colleagues developed a methodology for identifying if genome-scale models contain EGCs \[[@pcbi.1007533.ref057]\]. We applied it in two steps ([S7 File](#pcbi.1007533.s039){ref-type="supplementary-material"}): 1) Addition of Energy dissipation reactions (EDR) for ATP, GTP, CTP and UTP in the form: H~2~O\[c\] + XTP\[c\] -\> H\[c\] + XDP\[c\] + Pi\[c\] and 2) maximization of each EDR flux ***v***~***d***~ while no substrate uptake is allowed into the model as follows: $$\mathbf{\max}\mathbf{v}_{\mathbf{d}}$$ $$\mathbf{s}.\mathbf{t}\mspace{14mu}\mathbf{S}\mathbf{v} = 0$$ $$\forall\mathbf{i} \notin \mathbf{E}:\mspace{2mu}\mathbf{v}_{\mathbf{i}}^{\mathbf{L}\mathbf{B}} \leq \mathbf{v}_{\mathbf{i}} \leq \mathbf{v}_{\mathbf{i}}^{\mathbf{U}\mathbf{B}}$$ $$\forall\mathbf{i} \in \mathbf{E}:\mspace{2mu}\mathbf{v}_{\mathbf{i}} = 0$$

Here, ***S*** is the stoichiometric matrix, ***v*** the vector of fluxes, d the index of EDRs, $\mathbf{v}_{\mathbf{i}}^{\mathbf{L}\mathbf{B}}$ and $\mathbf{v}_{\mathbf{i}}^{\mathbf{U}\mathbf{B}}$ the vector of lower and upper bounds, respectively, and ***E*** is the set of indices of all exchange reactions of the model. If the optimal value of ***v***~***d***~ for this optimization is ***v***~***d***~\>**0**, there exist in the genome-scale model at least one EGC that is able to generate energy metabolites like ATP, GTP, CTP, or UTP.

Curation of TICs {#sec020}
----------------

Two types of modifications were performed on the curated Mtb genome-scale metabolic network in order to eliminate TICs \[[@pcbi.1007533.ref055]\].

i.  TICs formed by linearly dependent reversible reactions: Usually, these arise when there are two reactions (NAD^+^- and NADP^+^-dependent) with the same catalytic activity. In this instance, we forced the use of NADPH/NADP^+^ in anabolic reactions and NADH/NAD^+^ for catabolic reactions, as recommended by Pereira and colleague \[[@pcbi.1007533.ref038]\]. If two irreversible reactions that catalyze the forward and backward direction exist, both reactions (and GPR rules) are lumped together in just one reversible reaction.

ii. TICs formed by erroneous directionality assignments: we restricted the reaction directionality based on Gibbs free energy change (NExT algorithm) \[[@pcbi.1007533.ref095],[@pcbi.1007533.ref096]\] as long as gene essentiality predictions are not compromised

The later modification was based on the utilization of the NExT (network-embedded thermodynamic analysis) algorithm \[[@pcbi.1007533.ref095],[@pcbi.1007533.ref096]\]. This algorithm allows the identification of new irreversible reactions by calculating the thermodynamically feasible range of Gibbs energy of reactions and metabolite concentrations. NExT was implemented for those reactions participating in TICs under Matlab \[[@pcbi.1007533.ref096]\] with physiological conditions adapted for Mtb ([Table 4](#pcbi.1007533.t004){ref-type="table"}). In the absence of intracellular metabolite concentration data we assumed that all metabolites are between 0.0001 mM and 10 mM, which represents a range of observed physiological concentrations used by Martinez *et al* \[[@pcbi.1007533.ref095],[@pcbi.1007533.ref096]\].

10.1371/journal.pcbi.1007533.t004

###### Biophysical properties and concentration ranges for intracellular Mtb.
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  Properties                                 Values        Reference
  ------------------------------------------ ------------- ---------------------------------------------------------------------------------------------------
  Redox potential, cytosol                   -275 mV       Bhaskar et al., 2014 \[[@pcbi.1007533.ref097]\]
  pH, intracellular                          5.7           Zhang et al., 2003 \[[@pcbi.1007533.ref098]\]
  pH, extracellular (activated macrophage)   4.5           Rohde et al., 2007; Vandal et al., 2009 \[[@pcbi.1007533.ref099],[@pcbi.1007533.ref100]\]
  Ionic strength                             0.15 M        Kümmel et al., 2006; Martínez et al., 2014 \[[@pcbi.1007533.ref096],[@pcbi.1007533.ref101]\]
  Oxygen Concentration (mM)                  0.0001--0.1   Martínez et al., 2014 \[[@pcbi.1007533.ref102]\]
  \[CO~2~\],\[Pi\] (mM)                      1--100        Kümmel et al., 2006; Haraldsdóttir et al., 2012 \[[@pcbi.1007533.ref101],[@pcbi.1007533.ref103]\]
  Other metabolites (mM)                     0.0001--0.1   Martínez et al., 2014 \[[@pcbi.1007533.ref096]\]
  NADH/NAD                                   0.0001--0.1   Martínez et al., 2014 \[[@pcbi.1007533.ref096]\]
  NADPH/NADP                                 0.0001--0.1   Martínez et al., 2014 \[[@pcbi.1007533.ref096]\]

Standard Gibbs energy of formation (Δ~***f***~***G***~***i***~) (in kJ/mol), number of hydrogen atoms, and charge of all metabolites involved in TICs were obtained from the Biochemical Thermodynamic Calculator, eQuilibrator \[[@pcbi.1007533.ref104],[@pcbi.1007533.ref105]\].

If a reaction was specified to be reversible in the set of TICs and had its maximum Δ~***r***~***G*** calculated to be negative, the reaction is considered to occur in the forward direction. In contrast, if the minimum Δ~***r***~***G*** was positive, the reaction is considered to occur in the reverse direction. No direction can be inferred when the minimum Δ~***r***~***G*** is negative and the maximum is positive. Changes in directionality of reactions were done strictly when gene essentiality predictions in the curated genome-scale model were not compromised.

Gene essentiality analysis {#sec021}
--------------------------

To identify essential genes of Mtb grown on individual conditions (cholesterol minimal medium and glycerol minimal medium \[[@pcbi.1007533.ref062]\]), we use the Bayesian/Gumbel method of TRANSIT, version 2.02 \[[@pcbi.1007533.ref067]\]. The Bayesian/Gumbel method determines posterior probability of the essentiality of each gene (zbar). When zbar value is 1, or close to 1, the gene is considered essential (ES), if zbar is 0, or close to 0, the gene is considered non-essential (NE), uncertain (U) genes are those with zbar values between 0 and 1, and for too small (S) genes zbar is -1. After loading the TA count files (replicates for cholesterol and glycerol) and the gene annotation file into TRANSIT, and running the Gumbel method with default parameters, we obtained an output file with essentiality results ([S11](#pcbi.1007533.s016){ref-type="supplementary-material"} and [S12](#pcbi.1007533.s017){ref-type="supplementary-material"} Tables). Uncertain (U) and too small (S) genes were not taken into account for the *in silico* essentiality analysis. Minato and colleagues used the same statistical method to classify essential genes \[[@pcbi.1007533.ref065]\]. Conversely, DeJesus and colleagues \[[@pcbi.1007533.ref064]\] used a Hidden Markov Model based statistical method for classifying genes into four essentiality states: essential (ES), growth defect (GD), nonessential (NE), and growth advantage (GA). In order to evaluate the performance of the Mtb GSMNs to predict gene essentiality data, we used only binary classifiers, therefore we reclassify these genes just in two groups as follows: NE genes included NE and GA genes, and ES genes included GD and ES genes.

For the *in silico* gene essentiality analysis, we set the simulation conditions (asparagine, phosphate, sodium, ammonium, citrate, sulfate, zinc, calcium, chloride, Fe^3+^, Fe^2+^, and glycerol or cholesterol) according to Griffin minimal medium \[[@pcbi.1007533.ref062]\], 7H9 OADC medium, and "MtbYM" medium and a FBA-based gene essentiality analysis was performed in the eight Mtb models using the "single gene deletion" function of Cobra Toolbox ([S8 File](#pcbi.1007533.s040){ref-type="supplementary-material"}). Default maximization of biomass objective function was used to predict growth in all models. If a specific growth rate of no more than 5% of the wild-type was obtained, the gene was considered as essential (*in silico*), otherwise it was deemed non-essential.

Percentage of *in silico* gene essentiality predictions were categorized as: true-positive, false-positive, true-negative, and false-negative when the *in silico* data were compared with experimental essentiality data.

TP (true-positive): model simulation predicts no growth when essential genes are deleted.

FP (false-positive): model simulation predicts no growth when not essential genes are deleted.

TN (true-negative): model simulation predicts growth when not essential genes are deleted.

FN (false-negative): model simulation predicts growth when essential genes are deleted.

For evaluate the performance of the Mtb GSMNs we used sensitivity, specificity, accuracy, and Matthews Correlation Coefficient (MCC) metrics: $$\mathbf{s}\mathbf{e}\mathbf{n}\mathbf{s}\mathbf{i}\mathbf{t}\mathbf{i}\mathbf{v}\mathbf{i}\mathbf{t}\mathbf{y} = \frac{\mathbf{T}\mathbf{P}}{\mathbf{T}\mathbf{P} + \mathbf{F}\mathbf{N}}$$ $$\mathbf{s}\mathbf{p}\mathbf{e}\mathbf{c}\mathbf{i}\mathbf{f}\mathbf{i}\mathbf{c}\mathbf{i}\mathbf{t}\mathbf{y} = \frac{\mathbf{T}\mathbf{N}}{\mathbf{T}\mathbf{N} + \mathbf{F}\mathbf{P}}$$ $$\mathbf{A}\mathbf{c}\mathbf{c}\mathbf{u}\mathbf{r}\mathbf{a}\mathbf{c}\mathbf{y} = \frac{\left( {\mathbf{T}\mathbf{P} + \mathbf{T}\mathbf{N}} \right)}{\left( {\mathbf{T}\mathbf{P} + \mathbf{F}\mathbf{P} + \mathbf{T}\mathbf{N} + \mathbf{F}\mathbf{N}} \right)}$$ $$\mathbf{M}\mathbf{C}\mathbf{C} = \frac{\left( {\mathbf{T}\mathbf{P}*\mathbf{T}\mathbf{N}} \right) - \left( {\mathbf{F}\mathbf{P}*\mathbf{F}\mathbf{N}} \right)}{\sqrt{\left( {\mathbf{T}\mathbf{P} + \mathbf{F}\mathbf{P}} \right)\left( {\mathbf{T}\mathbf{P} + \mathbf{F}\mathbf{N}} \right)\left( {\mathbf{T}\mathbf{N} + \mathbf{F}\mathbf{P}} \right)\left( {\mathbf{T}\mathbf{N} + \mathbf{F}\mathbf{N}} \right)}}$$

Utilization of carbon and nitrogen sources {#sec022}
------------------------------------------

The methodology for modeling the effect of different carbon sources and nitrogen sources on Mtb growth was adapted from Lofthouse and colleagues \[[@pcbi.1007533.ref014]\]. The Biolog Phenotype MicroArray experiments classification used were obtained from Lofthouse and colleagues, 2013. They classified growth and no-growth in different carbon and nitrogen sources from the original Biolog data of Khatri and colleagues and the Roisin's minimal media \[[@pcbi.1007533.ref014],[@pcbi.1007533.ref072]\]. In addition, we used Roisin's minimal media data that also were obtained by Lofthouse and colleagues.

To model the carbon source experiment, we simulated the media as a modified form of Roisin's minimal media containing unlimited quantities of ammonia, phosphate, iron, sulfate, carbon dioxide and a Biolog carbon source influx of 1 mmol/gDW/h. Similarly, the nitrogen source experiment was simulated using a modified form of Roisin's media, where ammonia was replaced with 1 mmol/gDW/h of the Biolog nitrogen source and pyruvate was used as a carbon source (influx at 1 mmol/g DW/h).

To compare the utilization of carbon and nitrogen sources in all Mtb models with experimental data, we used Matthews Correlation Coefficient metrics ([Eq 8](#pcbi.1007533.e012){ref-type="disp-formula"}).

*In silico* growth predictions in carbon and nitrogen sources also were categorized as: true-positive, false-positive, true-negative, and false-negative.

TP (true-positive): model simulation predicts growth while growth is observed experimentally (or respiration rate is observed in Biolog phenotype microarrays) in presence of the unique carbon or nitrogen source.

FP (false-positive): model simulation predicts growth while no growth is observed experimentally in presence of the unique carbon or nitrogen source.

TN (true-negative): model simulation predicts no growth while no growth is observed experimentally in presence of the unique carbon or nitrogen source.

FN (false-negative): model simulation predicts no growth while growth is observed experimentally in presence of the unique carbon or nitrogen source.

Pathway utilization analysis {#sec023}
----------------------------

Pathway utilization analysis differences between sMtb2.0 and iEK1011_2.0 was based on FVA and flux sampling on Roisin's media (plus glycerol and oleic acid) using the default biomass objective functions.

The FVA was run by using the function "fluxVariability" of COBRA Toolbox v.3.0 and their results were compared with the Jaccard index for each reaction in CCM and EX reactions. As suggested by Haraldsdóttir and Colleagues \[[@pcbi.1007533.ref106]\] ([S4 File](#pcbi.1007533.s036){ref-type="supplementary-material"}), the Jaccard index can be defined as the ratio between the intersection and union of the flux ranges in the sMtb2.0 and iEK1011_2.0 models (Jaccard index of 0 means disjoint flux ranges and a Jaccard index of 1 indicates completely overlapping flux ranges). The mean Jaccard index means that there is an overall similarity between flux ranges of CCM and EX reactions in both Mtb models.

The coordinate hit-and-run with rounding (CHRR) \[[@pcbi.1007533.ref106]\] algorithm was used for sampling the solution space of both Mtb models. The COBRA function "sampleCbModel" was used for running the CHRR algorithm with the following parameters: the sampling density, nStepsPerPoint = 1848 and the number of samples, nPointsReturned = 5000. A Kruskal--Wallis test ([S4 File](#pcbi.1007533.s036){ref-type="supplementary-material"}) was used to assess whether flux samples generated using either the sMtb2.0 or iEK1011_2.0 constrained with Roisin's media stemmed from the same distribution \[[@pcbi.1007533.ref107]\].

Supporting information {#sec024}
======================

###### Overview of the eight constraint-based models of Mtb used in this study.

A document providing additional detail about the eight Mtb GSMNs used in this study.

(DOCX)

###### 

Click here for additional data file.

###### Curation of additional Thermodynamic Infeasible Cycles in sMtb2.0.

A document providing detailed description of the curation of TICs in sMtb2.0.

(DOCX)

###### 

Click here for additional data file.

###### Curation of additional Thermodynamic Infeasible Cycles in iEK1011_2.0.

A document providing detailed description of the curation of TICs in iEK1011_2.0.

(DOCX)

###### 

Click here for additional data file.

###### ROC curves of gene essentiality predictions for Mtb GSMNs.

**a** Receiver operating characteristic curve for the gene essentiality predictions in cholesterol minimal medium, **b** Receiver operating characteristic curve for the gene essentiality predictions in glycerol minimal medium, **c** Receiver operating characteristic curve for gene essentiality predictions in 7H9 Middlebrook OADC medium, **d** Receiver operating characteristic curve for gene essentiality predictions in MtbYM medium.

(TIF)

###### 

Click here for additional data file.

###### Central role of succinate dehydrogenase in oxidation of odd-chain substrates.

(TIF)

###### 

Click here for additional data file.

###### Set analysis of genes from all the eight Mtb GSMNs.

A table with pairwise comparisons, unions, and intersections of genes annotated in the eight GSMNs of Mtb.

(XLSX)

###### 

Click here for additional data file.

###### Metabolic pathways associated to all the intersected gene sets of Mtb GSMNs.

(XLSX)

###### 

Click here for additional data file.

###### Genes and metabolic pathways shared between GSMNs of Mtb.

(XLSX)

###### 

Click here for additional data file.

###### Network topological properties of Mtb GSMNs.

(XLSX)

###### 

Click here for additional data file.

###### List of unbalanced reactions and Metabolites without formulas in the Mtb GSMNs.

(XLSX)

###### 

Click here for additional data file.

###### List of literature used in the macromolecular composition of biomass reactions of GSMN-TB and iNJ661.

(XLSX)

###### 

Click here for additional data file.

###### Biomass growth rates in complete medium.

(XLSX)

###### 

Click here for additional data file.

###### Differences in stoichiometric coefficients of BIOMASS_2 from iEK1011 compared with default biomass objective functions of sMtb and iOSDD890.

(DOCX)

###### 

Click here for additional data file.

###### List of blocked reactions and dead-end metabolites.

(XLSX)

###### 

Click here for additional data file.

###### List of Thermodynamically infeasible cycles identified for the eight Mtb GSMNs.

(XLSX)

###### 

Click here for additional data file.

###### Transposon sequencing analysis of Mtb genes required for growing on minimal medium plus cholesterol.

A list of genes of Mtb classified as essential, non-essential, and uncertain for growing in cholesterol minimal medium, the essentiality analysis was obtained by applying the Bayesian/Gumbel Method incorporated into the software TRANSIT.

(XLSX)

###### 

Click here for additional data file.

###### Transposon sequencing analysis of Mtb genes required for growing on minimal medium plus glycerol.

A list of genes of Mtb classified as essential, non-essential, and uncertain for growing in glycerol minimal medium, the essentiality analysis was obtained by applying the Bayesian/Gumbel Method incorporated into the software TRANSIT.

(XLSX)

###### 

Click here for additional data file.

###### Predictive power of Mtb GSMNs for classifying essential and non-essential genes on cholesterol minimal medium.

Genes whose *in silico* knockouts give growth rate values lesser than 5% of the maximum growth rate are classified as essential, otherwise are classified as non-essential.

(XLSX)

###### 

Click here for additional data file.

###### Predictive power of Mtb GSMNs for classifying essential and non-essential genes on glycerol minimal medium.

Genes whose *in silico* knockouts give growth rate values lesser than 5% of the maximum growth rate are classified as essential, otherwise are classified as non-essential.

(XLSX)

###### 

Click here for additional data file.

###### Predictive power of Mtb GSMNs for classifying essential and non-essential genes on 7H9 OADC medium.

Genes whose *in silico* knockouts give growth rate values lesser than 5% of the maximum growth rate are classified as essential, otherwise are classified as non-essential.

(XLSX)

###### 

Click here for additional data file.

###### Predictive power of Mtb GSMNs for classifying essential and non-essential genes on YM rich medium.

*In silico* gene knockouts that have growth rates of less than 5% of the wild type growth rate are classified as essential, otherwise are classified as non-essential.

(XLSX)

###### 

Click here for additional data file.

###### List of common False Positive and False Negative Genes of all the Mtb GSMNs during gene essentiality predictions.

(XLSX)

###### 

Click here for additional data file.

###### Predictive power of Mtb GSMNs growing on sole carbon sources.

(XLSX)

###### 

Click here for additional data file.

###### Predictive power of Mtb GSMNs growing on sole nitrogen sources.

(XLSX)

###### 

Click here for additional data file.

###### New added reactions into the sMtb and iEK1011 models.

(XLSX)

###### 

Click here for additional data file.

###### List of reactions with modified gene annotation in sMtb2.0.

(XLSX)

###### 

Click here for additional data file.

###### Null Space of the stoichiometric matrix formed by unbounded reactions of sMtb2.0 and iEK1011_2.0.

(XLSX)

###### 

Click here for additional data file.

###### Gibbs free energy change of Unbounded Reactions of updated Mtb GSMNs.

(XLSX)

###### 

Click here for additional data file.

###### Gene Essentiality Predictions for iEK1011_2.0 and sMtb2.0 on four Mtb media.

(XLSX)

###### 

Click here for additional data file.

###### Growth Phenotypes of iEK1011_2.0 and sMtb2.0 on unique carbon and nitrogen sources.

(XLSX)

###### 

Click here for additional data file.

###### FVA flux ranges and FBA fluxes sMtb2.0 and iEK1011_2.0 growing on Roisin's media, using the default biomass objective function as constraints.

(XLSX)

###### 

Click here for additional data file.

###### FVA and FBA fluxes of sMtb2.0 and iEK1011_2.0 growing on Roisin's medium without a defined biomass objective function.

(XLSX)

###### 

Click here for additional data file.

###### Biomass growth rate comparison across Mtb GSMNs.

(ZIP)

###### 

Click here for additional data file.

###### Matlab scripts for identifying unbounded reactions and thermodynamically infeasible cycles in Mtb GSMNs.

(ZIP)

###### 

Click here for additional data file.

###### MEMOTE reports for iEK1011_2.0 and sMtb2.0.

(ZIP)

###### 

Click here for additional data file.

###### Matlab script of FVA, FBA and Uniform Sampling for exploring solution space of iEK1011_2.0 and sMtb2.0.

(ZIP)

###### 

Click here for additional data file.

###### Updated Mtb models sMtb2.0 and iEK1011_2.0 are in.mat, json, sbml, and xlsx format.

(ZIP)

###### 

Click here for additional data file.

###### Matlab script for checking the charge and mass balance of Mtb GSMNs.

(ZIP)

###### 

Click here for additional data file.

###### Matlab scripts for identifying Mtb GSMNs with Energy Generating Cycles.

(ZIP)

###### 

Click here for additional data file.

###### Matlab scripts for gene essentiality analysis of Mtb GSMNs on four media conditions.

(ZIP)

###### 

Click here for additional data file.
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Dear Dr Beste,

Thank you very much for submitting your manuscript \'A systematic evaluation of Mycobacterium tuberculosis Genome-Scale Metabolic Networks\' for review by PLOS Computational Biology. Your manuscript has been fully evaluated by the PLOS Computational Biology editorial team and in this case also by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. While your manuscript cannot be accepted in its present form, we are willing to consider a revised version in which the issues raised by the reviewers have been adequately addressed. We cannot, of course, promise publication at that time.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

Your revisions should address the specific points made by each reviewer. Please return the revised version within the next 60 days. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by email at <ploscompbiol@plos.org>. Revised manuscripts received beyond 60 days may require evaluation and peer review similar to that applied to newly submitted manuscripts.

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A detailed list of your responses to the review comments and the changes you have made in the manuscript. We require a file of this nature before your manuscript is passed back to the editors.

\(2\) A copy of your manuscript with the changes highlighted (encouraged). We encourage authors, if possible to show clearly where changes have been made to their manuscript e.g. by highlighting text.

\(3\) A striking still image to accompany your article (optional). If the image is judged to be suitable by the editors, it may be featured on our website and might be chosen as the issue image for that month. These square, high-quality images should be accompanied by a short caption. Please note as well that there should be no copyright restrictions on the use of the image, so that it can be published under the Open-Access license and be subject only to appropriate attribution.

Before you resubmit your manuscript, please consult our Submission Checklist to ensure your manuscript is formatted correctly for PLOS Computational Biology: <http://www.ploscompbiol.org/static/checklist.action>. Some key points to remember are:

\- Figures uploaded separately as TIFF or EPS files (if you wish, your figures may remain in your main manuscript file in addition).

\- Supporting Information uploaded as separate files, titled Dataset, Figure, Table, Text, Protocol, Audio, or Video.

\- Funding information in the \'Financial Disclosure\' box in the online system.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com> PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see [here](http://journals.plos.org/ploscompbiol/s/submission-guidelines#loc-materials-and-methods). 
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Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: In this paper, the authors evaluate 8 published genome-scale models (GEMs) of M. tuberculosis H3Rv and refine the best performing GEMs for future use. Specifically, the authors compare the gene content, currency metabolite connectivity, biomass reactions, charge balance, mass balance, blocked reactions, thermodynamics, gene essentiality predictions, and utilization of carbon sources across the different models. The authors use standard metrics to assess the various model performances and also place the model predictions within the context of TB literature to help discern biological relevance. The authors identify iEK1011 and sMtb2018 as the best overall GEM and improve their quality by adding various metabolic reactions to the models with detailed reasons. Given the power of GEMs to enable deep analysis of TB metabolism, as well as the large availability and variability in TB GEMs, we believe that this study adds significant value to the TB research community and thus should be published in PLOS Computational Biology. However, there are more GEM evaluations and details described below in the major comments that we would like to see the authors address before publication. In particular, we would like to see the authors detail differences in pathway utilization strategies between the improved models, if there are any.

To the Authors:

Major comments

1\. It is highly recommended by the COBRA community that the authors provide a MEMOTE report of both the compared and improved reconstructions (<https://www.biorxiv.org/content/10.1101/350991v1>). Rather than dictating whether the models are worthy of being published, the MEMOTE report should help understand what the limitations are and where they should focus their efforts in potentially improving the model. Importantly, the MEMOTE report may help the authors improve improve the refined models and comparisons before publication.

2\. The authors should additionally provide the improved reconstructions in both json and sbml format.

The authors should add another section detailing the different biomass reactions across the models (i.e., metabolite composition, metabolite weightings, shadow prices, etc). Currently, only a comparison of the biomass molecular weight is provided at the end of the "Checking mass and charge balances of biochemical reactions" section.

3\. The authors should provide a description/comparison of the growth-associated maintenance (GAM) or non-growth associated maintenance (NGAM) reactions across the different TB models. One or two sentences is sufficient.

4\. Both flux variability analysis (FVA) and flux sampling are key FBA tools used to evaluate the solution space of GEMs. We recommend that the authors perform FVA and flux sampling of the improved GEMs (iEK1011_2.0 and sMtb2.0) to both evaluate the flux bottlenecks and distributions between models.

5\. Continuing from comment 5, the authors should provide detailed comparisons of the flux profile between the improved GEMs (iEK1011_2.0 and sMtb2.0) in standard TB media using either parsimonious FBA (pFBA), FVA, or flux sampling. For example, do the models prefer different nutrients? Do they have similar flux strategies in TCA and oxPPP? We would like to see the authors detail differences in pathway utilization strategies between the improved models, if there are any.

Minor comments

1\. Line 100: The description of red in Fig 2 is written the same as blue.

Reviewer \#2: In their manuscript titled "A systematic evaluation of Mycobacterium tuberculosis Genome-Scale Metabolic Networks" Lope-agudelo et al. have systematically examined 8 of the most recent Mtb GEM models and have identified a significant number of problems with them. As I note below, I have questions about some of their choices but overall, I congratulate and thank the authors for a detailed examination of models for an organism of significant importance.

Despite this, I don't find the work novel and suited for Plos Computational biology. I expect Plos Comp bio papers to either introduce a novel computational biology method or report a significant biological find. Neither of these apply to this paper. The manuscript is better suited for more general journals like Plos One or Scientific reports.

Perhaps if the authors had generated a single unified improved model of Tb metabolism, then it would have been appropriate for Plos Comp Bio. As it stands, by their own admission, one of their models is better suited for interacting with Recon model while the other is better suited for simulating growth under a variety of different conditions.

Major concerns

• The paragraph starting on line 38 is not sufficient to describe the examined models and how they differ. The order of publication and combination of models is included in figure 1 and further detail is provided in S1 but there is no mention of it in the main text.

• The model with the greatest number of reactions and genes is iAB-AMF-1410-Mt-661 updated published on 2017. Why was this model ignored? There is no mention of this model. How can the purported updated models be considered most complete if they still have fewer reactions and genes than the noted model?

• Examining figure 2 it is obvious that some models are just the old models plus some new reactions e.g. sMtb and sMtb2018. Why include the former when instead iAB-AMF-1410-Mt-661 could have been examined?

• Line 63, what do you mean by multi-scale simulation platform? What scales are you talking about?

• Line 92, I'm confused about the statement "has poor annotation of genes"? Does that mean the genes identified were incorrectly assigned a function or that the coverage of the pathways was lacking?

• How does iCG760 operate as a system-level model without water as one of its metabolites? To me the sorry biochemical states of three of the published models is the most shocking find of the paper.

• When highlighting the results of analyses for blocked reactions and dead-end metabolites it is important to note if the cause is due to gaps in genome or incomplete GPRs. The former could be viewed as the modeler trying not to add a new phenotype without experimental validation whereas the latter is a poorly curated model.

• Why not combine sMtb2.0 and iEK1011_2.0 into one unified model that would work well with Recon for host pathogen interactions as well as correctly predicts growth on a variety of different compounds? That would be the perfect outcome from your extensive efforts.

Minor concerns

• Do not use acronyms in the abstract prior to defining them, i.e. TB

• Some figures are labeled Fig. others Figure. Please choose one format.

• The sentence starting on line 152 is incomplete.

Reviewer \#3: The article entitled, \'A systematic evaluation of Mycobacterium tuberculosis Genome-Scale Metabolic Networks\', Lopez-Agudelo et al present a comparative analysis of Mtb genome scale metabolic reconstructions.

This is a welcome analysis in the literature, given the growing number of models and derivations of models and the need for reconciliation and assessment of the current state. While the most recent update iEK1011 presented an update, the authors identify aspects of the model that area missing.

\+ Figure 1: Provides a nice summary of an otherwise confusing development of multiple models using genome-scale models of Mtb.

\+ p7: How did the authors arrive at the cutoff of 10% for the deviation of 1 g/mmol? Why is iEK1011 so much higher than some of the other models?

\+ Fig 5: It is understandable to revise reaction directionality based on thermodynamic feasibility assessment, however to remove a particular reaction(s) (DFRA1 and DFRA3) should require a little more justification, including any experimental support/arguments and/or explanations of why the arguments made for a different genus (yeast) are also relevant for Mtb.

\+ p13: the identification of a need for a menaquinone-dependent succinate dehydrogenase reaction is an interesting modification that appeared to improve the predictive capability of the model. However the authors state that they had to add this reaction to iEK1011, whereas in reality all that was required was to change this from an irreversible to a reversible reaction. It would be helpful to note whether there is experimental evidence to suggest that concentrations are present to enable thermodynamic reversibility of the reaction. Additionally, will the reversible form of the reaction result in any infeasible reaction cycles?

\+ p16: similar to the question raised on p13, which one of these involved addition of new reactions vs making reactions reversible

\+ p18: \'thermodynamically unstable\' \-- perhaps the authors meant thermodynamically infeasible, since there does not appear to be any discussion of stability of particular flux states

\+ p17: what specifically is meant by \"unblocking B12 synthesis\"? The authors themselves cite specific articles that highlight the incomplete knowledge about B12 handling in Mtb.

\+ p17: it is not clear what addition is made by addition of biotin?

\+ p17: again, it is not clear what specifically the authors mean by \"including \... pyridoxal-5-phosphate\", although from the referenced article, in this case they presumably are referring to the addition of pyridoxal 5\' synthase. For biotin, it is not clear what revisions they made or the rational/justification for it.

\+ Table 5: it is not clear where the cited values for O2, NADH/NAD, and NADPH/NADP are obtained from the referenced citations, since the paper and textbook (non-specific reference) do not appear to cite measurements for Mtb. Additionally it is not clear what is meant by \"Other metabolites\".

\+ p26: What was the scientific rationale/calculation to identify the 5% cutoff for

\+ minor comments:

there are a number of small grammatical errors, e.g.

p13, l255: \"is as a result\"

p16, l312: \"exempler\", did you mean exemplar?

p 29: supplemental file legends: S10, S11, S12, S13, \"for classify essential\"

etc.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Computational Biology* [data availability policy](http://journals.plos.org/ploscompbiol/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.
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Dear Dr. Beste,

Thank you very much for submitting your manuscript \"A systematic evaluation of Mycobacterium tuberculosis Genome-Scale Metabolic Networks\" for consideration at PLOS Computational Biology. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. 

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.
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Anders Wallqvist
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Reviewer \#3: The revised version provides clarifications for many of the points that were raised. Further the incorporation of MEMOTE report, as suggested by a different reviewer, is a nice addition.

A few follow up points are worth addressing,

\+ Regarding the question of Vitamin B12 synthesis, regardless of whether another paper has included the pathway based on 'physiological' argument is generally not considered sufficient criteria for incorporating content into genome-scale metabolic networks (especially if the purpose of the manuscript is to provide clarity in a field with multiple versions of models). Generally even if 'physiological' evidence arguments are made, this typically involves inclusion of a single enzyme or transporter, thus the inclusion of multiple enzymatic steps introduces the potential for significant error into the model.

The manuscript by Minas et al poses a possible pathway, but lacks any strong biochemical evidence for the actual enzymes and pathway. The authors should clearly identify which enzymes/reactions were added. Microbial vitamin B12 synthesis is not a trivial or singular pathway, as recently summarized by Fang et al, Microbial production of vitamin B12: a review and future perspectives, DOI 10.1186/s12934-017-0631-y. It should clearly be stated which enzymes/reactions were added and ideally some type of justification (it is recognized that in the absence of direct evidence

\+ "We also included the co-factors biotin and pyridoxal-5-phosphate in the biomass formulation to enhance the phenotype prediction of sMtb2018 and iEK1011 as recommended by Xavier et al. \[19\]."

The argument that the authors defer to Xavier et al regarding inclusion of pyridoxa-5-phosphate into the model, is not the standard that genome-scale reconstructions are typically constructed with. However by provided two versions of the biomass function ("BiomassGrowth_2.0" and "BIOMASS\_\_2.1"), this issue is adequately addressed.

\+ There are still a few grammatical/spelling errors, e.g. Mathews Correlation Coefficient should read Matthews Correlation Coefficient, the authors likely mean 'bona fide' and not 'bone-fide' on page 10, etc. Recommend one more read through by authors to minimize misspellings.
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Dear Dr. Beste,

We are pleased to inform you that your manuscript \'A systematic evaluation of Mycobacterium tuberculosis Genome-Scale Metabolic Networks\' has been provisionally accepted for publication in PLOS Computational Biology.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Computational Biology. 

Best regards,

Anders Wallqvist
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Deputy Editor
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Dear Dr Beste,

I am pleased to inform you that your manuscript has been formally accepted for publication in PLOS Computational Biology. Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out, the early version of your manuscript will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Computational Biology and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Sarah Hammond
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